Attached files

file filename
EX-10.1 - EXHIBIT 10.1 - PLURISTEM THERAPEUTICS INCexhibit_10-1.htm
10-Q - 10-Q - PLURISTEM THERAPEUTICS INCzk1719875.htm
EX-32.3 - EXHIBIT 32.3 - PLURISTEM THERAPEUTICS INCexhibit_32-3.htm
EX-32.2 - EXHIBIT 32.2 - PLURISTEM THERAPEUTICS INCexhibit_32-2.htm
EX-31.3 - EXHIBIT 31.3 - PLURISTEM THERAPEUTICS INCexhibit_31-3.htm
EX-31.2 - EXHIBIT 31.2 - PLURISTEM THERAPEUTICS INCexhibit_31-2.htm
EX-31.1 - EXHIBIT 31.1 - PLURISTEM THERAPEUTICS INCexhibit_31-1.htm

 
Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
 
In connection with the Quarterly Report (the “Report”) of Pluristem Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, Zami Aberman, Co-Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:  May 8, 2017


 
By: /s/ Zami Aberman
——————————————
Zami Aberman
Co-Chief Executive Officer